– USA, NY – Tyme, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of Don DeGolyer to the Company’s board of directors.
Mr. DeGolyer is the founder, Chief Executive Officer, and a director of Vertice Pharma, LLC, a specialty pharmaceuticals company focused on improving patients’ health. He was previously the Chief Operating Officer of Endo Pharmaceuticals and, before that, served as President & CEO of Sandoz North America. Mr. DeGolyer also held various leadership roles at Pfizer, Johnson & Johnson and Novartis, in all totaling over 30 years of experience in the pharmaceuticals industry.
Mr. DeGolyer will be an independent director and a member of the Company’s audit committee. In conjunction with Mr. DeGolyer’s election and appointment to the audit committee, director Paul Sturman has stepped down from the audit committee. Mr. Sturman continues to serve as the chairman of the compensation committee of the Board.
“We are delighted to have Don joining our board,” said Steve Hoffman, Chief Executive Officer of Tyme. “His extensive industry experience and successful track record in manufacturing and commercialization will be a real asset for Tyme as we continue into an important period for the company.”
About Tyme Technologies
Tyme Inc., is a clinical-stage biotechnology company developing cancer therapeutics that are intended to be broadly effective across tumor types and have low toxicity profiles. Unlike targeted therapies that attempt to regulate specific mutations within cancer, the Company’s therapeutic approach is designed to take advantage of a cancer cell’s innate metabolic weaknesses to compromise its defenses, leading to cell death through oxidative stress and exposure to the body’s natural immune system.
For more information : http://www.tymeinc.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.